These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1130 related items for PubMed ID: 8124252

  • 1. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T, Schattenberg A, Preijers F, Raymakers R, Muus P, Wessels J.
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
    Schattenberg A, De Witte T, Preijers F, Raemaekers J, Muus P, Van der Lely N, Boezeman J, Wessels J, Van Dijk B, Hoogenhout J.
    Blood; 1990 Mar 15; 75(6):1356-63. PubMed ID: 2310832
    [Abstract] [Full Text] [Related]

  • 3. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients.
    Schattenberg A, Schaap N, Preijers F, van der Maazen R, de Witte T.
    Bone Marrow Transplant; 2000 Jul 15; 26(1):17-22. PubMed ID: 10918401
    [Abstract] [Full Text] [Related]

  • 4. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F, Granena A, Gahrton G, De Witte T, Gratwohl A, Reiffers J, Gorin NC.
    Bone Marrow Transplant; 1996 Jan 15; 17(1):13-8. PubMed ID: 8673048
    [Abstract] [Full Text] [Related]

  • 5. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr 15; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 6. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
    Schattenberg A, Preijers F, Mensink E, Bär B, Schaap N, Geurts van Kessel A, van der Maazen R, de Witte T.
    Bone Marrow Transplant; 1997 Jun 15; 19(12):1205-12. PubMed ID: 9208114
    [Abstract] [Full Text] [Related]

  • 7. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.
    Clin Transplant; 1998 Apr 15; 12(2):84-92. PubMed ID: 9575394
    [Abstract] [Full Text] [Related]

  • 8. Prevention of graft-versus-host disease by lymphocyte depletion of the bone marrow graft with use of counterflow centrifugation.
    Haanen C, De Witte T, Plas A, Schattemberg T.
    Haematologica; 1991 Mar 15; 76 Suppl 1():22-8. PubMed ID: 1864551
    [Abstract] [Full Text] [Related]

  • 9. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow.
    Bär BM, Schattenberg A, De Man AJ, Hoogenhout MJ, Boezeman J, de Witte T.
    Bone Marrow Transplant; 1992 Jul 15; 10(1):45-52. PubMed ID: 1515878
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C, Aversa F, Raymondi C, Marsella AR, Panizza BM, Perrucci E, Piro F, Maranzano E, Lupattelli M, Martelli MF, Latini P.
    Cancer J Sci Am; 1996 Jul 15; 2(6):330-4. PubMed ID: 9166553
    [Abstract] [Full Text] [Related]

  • 11. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
    Gale RP, Horowitz MM.
    Bone Marrow Transplant; 1990 Jul 15; 6 Suppl 1():94-7. PubMed ID: 2390646
    [Abstract] [Full Text] [Related]

  • 12. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ.
    Bone Marrow Transplant; 1998 Mar 15; 21(6):543-51. PubMed ID: 9543057
    [Abstract] [Full Text] [Related]

  • 13. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.
    Bone Marrow Transplant; 2003 Jan 15; 31(2):121-8. PubMed ID: 12621494
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J, Powles R, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Middleton G, Eisen T, Singhal S.
    Bone Marrow Transplant; 1996 Oct 15; 18(4):741-6. PubMed ID: 8899189
    [Abstract] [Full Text] [Related]

  • 15. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan 15; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R.
    Exp Hematol; 1995 Dec 15; 23(14):1553-62. PubMed ID: 8542946
    [Abstract] [Full Text] [Related]

  • 17. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP.
    Biol Blood Marrow Transplant; 2009 Feb 15; 15(2):257-65. PubMed ID: 19167686
    [Abstract] [Full Text] [Related]

  • 18. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.
    Bone Marrow Transplant; 1994 Nov 15; 14(5):751-7. PubMed ID: 7889008
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Nov 15; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
    Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, Dipersio J, Adkins D.
    Biol Blood Marrow Transplant; 2004 May 15; 10(5):310-9. PubMed ID: 15111930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.